image credit- freepik
PharmaEssentia Corporation, a global biopharmaceutical company headquartered in Taiwan with deep expertise in the development of novel biologics for hematology and oncology, and its US subsidiary PharmaEssentia USA Corporation have announced that the global corporate Board of Directors has approved an investment of approximately $46 million to establish a new, wholly owned manufacturing subsidiary in Puerto Rico.
The planned investment supports the company’s global manufacturing expansion strategy and is intended to serve as a future manufacturing centre for the US market and long-term global demand for BESREMi® (ropeginterferon alfa-2b).
The investment reflects sustained global demand growth for BESREMi®, particularly in the United States, as well as the potential additional demand growth from regulatory approvals of BESREMi® for new uses. BESREMi® holds orphan drug designation in the United States for the treatment of polycythemia vera (PV) in adults.
Puerto Rico is widely recognised as a leading global hub for pharmaceutical manufacturing, hosting a strong ecosystem of experienced talent, infrastructure, and regulatory expertise. The planned manufacturing facility is expected to provide several long-term strategic benefits for PharmaEssentia, including enhanced supply security, increased operational flexibility, improved cost efficiency, and scalable manufacturing capacity to support future growth.
“PharmaEssentia’s decision to establish a manufacturing operation in Puerto Rico underscores the island’s role as a strategic US hub for life sciences and advanced manufacturing,” said Governor of Puerto Rico Jennifer González. “This investment strengthens supply-chain resilience, creates high-value jobs, and reinforces Puerto Rico’s position as a trusted location for biopharmaceutical innovation and production serving patients in the United States and around the world.”
